A Related Study Of PRAME Gene Expression In Haematological Malignancy

Objective To determine clinical significance of PRAME gene in CML, lymphoma and MM and its implications for monitoring minimal residual disease in haematological malignancy.Methods The expression of PRAME mRNA was detected in 36 CML, 20 lymphoma, 20 MM, 10 normal subjects and one AL cell-line(K562) by using semi-quantitative RT-PCR and compared with the expression of BCR/ABL in 36 CML. Long-term follow-up monitoring of PRAME expression was performed in 1 patient with MM.Results PRAME mRNA was negative in bone marrow cells from 10 normal subjects. PRAME gene was expressed in 22.2% (n=8) CML patients, of which, 16.7%(n=l)CML-AP patients and 46.7%(n=7)CML-BC patients, but PRAME gene in CML-CP was all negative. The expression of PRAME had significant difference between CML-CP, CML-AP and CML-BC ( P<0.05). BCR/ABL gene was revealed in 35 of 36 CML patients(97.2%) and its expression had no correlation with PRAME gene(P>0. 05). Only 2 NHL were detected the expression of PRAME gene. It had no significant difference with normal group(P>0. 05). In addition, We analyzed 20 bone marrow samples from patients with MM for the expression of PRAME gene. PRAME gene in all of the samples of patients with stage I and stage II myeloma were found negative, 4 PRAME-positive patients were in stage III (28.6%). PRAME expression was not correlated to the white blood count, hemoglobin, platelet count and the percentage of blasts, also independent of age and gender. Long-term follow-up monitoring of PRAME expression was performed in 1 patient with MM which...